{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T06:17:24Z","timestamp":1785651444398,"version":"3.56.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background\/Objectives<\/jats:title><jats:p>Patients with ovarian cancer commonly experience metastases and recurrences, which contribute to high mortality. Our objective was to better understand ovarian cancer metastasis and identify candidate biomarkers and drug targets for predicting and preventing ovarian cancer recurrence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Transcripts of 770 cancer-associated genes were compared in cells collected from ascitic fluid versus resected tumors of an ES-2 orthotopic ovarian cancer mouse model. Associated cell types and pathways were explored with bioinformatics. FGF7 protein was measured using capillary-based immunoassays or ELISA in mouse and clinical specimens. Significances of differential gene expression and patient prognosis were determined by volcano plot and log-rank test, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Tumor transcriptomes exhibited higher endothelial cells, oxygenation, proteasome activity, and metabolism in comparison to ascites, but similar percentages of cancer-associated fibroblasts and immune cells. FGF7 mRNA was significantly higher in mouse tumors compared to ascites. FGF7 protein was significantly higher in tumors than in ascites in independent mouse models and clinical specimens. Serum FGF7 protein levels above the median of 25 patients with ovarian cancer were associated with worse progression-free and overall survival (p = 0.005 and 0.019, respectively) independent of patient and tumor characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In comparison to ascites, tumors exhibit different transcriptomic profiles that identify candidate biomarkers and drug targets for predicting and preventing recurrence. Among these, elevated tumoral FGF7 validated at the protein level and elevated serum FGF7 were significantly associated with worse patient survival. These results support further development of FGF7 receptor-targeted drugs and serum FGF7 to prevent and predict recurrence, respectively.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1524606","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T05:10:49Z","timestamp":1737004249000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Implication of fibroblast growth factor 7 in ovarian cancer metastases and patient survival"],"prefix":"10.3389","volume":"14","author":[{"given":"Laura F.","family":"Mortan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke A.","family":"Meelheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Garland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline A.","family":"Bohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitha Redempta","family":"Isingizwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris M.","family":"Benbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1186\/s40064-016-2660-0","article-title":"Management of relapsed ovarian cancer: a review","volume":"5","author":"Giornelli","year":"2016","journal-title":"SpringerPlus"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FRalpha-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.3390\/cancers13225756","article-title":"Maintenance treatment of newly diagnosed advanced ovarian cancer: time for a paradigm shift","volume":"13","author":"DiSilvestro","year":"2021","journal-title":"Cancers"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.3390\/cancers15112980","article-title":"To bev or not to bev during ovarian cancer maintenance therapy","volume":"15","author":"Sznurkowski","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"8412","DOI":"10.3390\/ijms23158412","article-title":"PARP inhibitors: clinical limitations and recent attempts to overcome them","volume":"23","author":"Kim","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174318","article-title":"Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response","volume":"13","author":"Rickard","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M114.041194","article-title":"Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication","volume":"13","author":"Shender","year":"2014","journal-title":"Mol Cell Proteom"},{"key":"B11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","article-title":"The untapped potential of ascites in ovarian cancer research and treatment","volume":"123","author":"Ford","year":"2020","journal-title":"Br J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2020.11.017","article-title":"Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine","volume":"9","author":"Guo","year":"2022","journal-title":"Genes Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.3390\/cancers12061470","article-title":"An overview of candidate therapeutic target genes in ovarian cancer","volume":"12","author":"Alexandrova","year":"2020","journal-title":"Cancers"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2174\/1389450120666191016143836","article-title":"Exploring the clinical impact of predictive biomarkers in serous ovarian carcinomas","volume":"21","author":"Le Page","year":"2020","journal-title":"Curr Drug Targets"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13148-018-0602-0","article-title":"Epigenetic therapy for ovarian cancer: promise and progress","volume":"11","author":"Moufarrij","year":"2019","journal-title":"Clin Epigen"},{"key":"B16","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3390\/cancers15030893","article-title":"Amino acid-metabolizing enzymes in advanced high-grade serous ovarian cancer patients: value of ascites as biomarker source and role for IL4I1 and IDO1","volume":"15","author":"Grobben","year":"2023","journal-title":"Cancers"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2014.03.016","article-title":"Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers","volume":"8","author":"Moisan","year":"2014","journal-title":"Mol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1272","article-title":"CRISPR\/cas9-mediated trp53 and brca2 knockout to generate improved murine models of ovarian high-grade serous carcinoma","volume":"76","author":"Walton","year":"2016","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/21.4.585","article-title":"Development of a syngeneic mouse model for events related to ovarian cancer","volume":"20","author":"Roby","year":"2000","journal-title":"Carcinogenesis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"42","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B21","unstructured":"Cran-package fpc\n          \n          \n            \n              Hennig\n              C"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz363","article-title":"Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology","volume":"35","author":"Sturm","year":"2019","journal-title":"Bioinformatics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16257","article-title":"Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer","volume":"181","author":"Gy\u0151rffy","year":"2024","journal-title":"Br J Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"100625","DOI":"10.1016\/j.xinn.2024.100625","article-title":"Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors","volume":"5","author":"Gy\u0151rffy","year":"2024","journal-title":"Innovation (Camb)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds300","article-title":"New insights into ovarian cancer pathology","volume":"23","author":"Prat","year":"2012","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12967-024-05085-y","article-title":"Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter","volume":"22","author":"Feng","year":"2024","journal-title":"J Trans Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.4161\/cbt.10.5.12585","article-title":"Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer","volume":"10","author":"Cole","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204755","article-title":"Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer","volume":"20","author":"Steele","year":"2001","journal-title":"Oncogene"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.235353","article-title":"Keratinocyte growth factor binding to fibroblast growth factor receptor 2-IIIb promotes epithelial ovarian cancer cell proliferation and invasion","volume":"14","author":"Wu","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-016-0404-1","article-title":"Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies","volume":"35","author":"Tyulyandina","year":"2017","journal-title":"Invest New Drug"},{"key":"B33","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10555-007-9094-7","article-title":"Tumour vascularization: sprouting angiogenesis and beyond","volume":"26","author":"Hillen","year":"2007","journal-title":"Cancer Metast Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148103","article-title":"A phase 2 study of pemigatinib (FIGHT-203; INCB054828) in patients with myeloid\/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement (MLN)","volume":"138","author":"Gotlib","year":"2021","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS4135","article-title":"FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in","volume":"36","author":"Catenacci","year":"2018","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2196\/25976","article-title":"Long-term survival among histological subtypes in advanced epithelial ovarian cancer: population-based study using the surveillance, epidemiology, and end results database","volume":"7","author":"Yang","year":"2021","journal-title":"JMIR Public Health surveill"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2014-202430","article-title":"Caution over use of ES2 as a model of ovarian clear cell carcinoma","volume":"67","author":"Kwok","year":"2014","journal-title":"J Clin Pathol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.26502\/ogr072","article-title":"ES-2 ovarian cancer cells present a genomic profile inconsistent with their reported history","volume":"4","author":"Devor","year":"2021","journal-title":"Obstet Gynecol Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.v11.11","article-title":"The multicellular signalling network of ovarian cancer metastases","volume":"11","author":"Sommerfeld","year":"2021","journal-title":"Clin Transl Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1524606\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T05:10:56Z","timestamp":1737004256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1524606\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":40,"alternative-id":["10.3389\/fonc.2024.1524606"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1524606","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"article-number":"1524606"}}